menu
    • menu
    [{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management and Research Company LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"Lutetium-177","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"SHINE Technologies","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SHINE Technologies \/ Fidelity Management and Research Company LLC","highestDevelopmentStatusID":"1","companyTruncated":"SHINE Technologies \/ Fidelity Management and Research Company LLC"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"177Lu-rosopatamab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SHINE Technologies \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SHINE Technologies \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Glytherix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"177Lu-DOTA-Miltuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SHINE Technologies \/ SHINE Technologies","highestDevelopmentStatusID":"14","companyTruncated":"SHINE Technologies \/ SHINE Technologies"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"WARF Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"177Lu-ART-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SHINE Technologies \/ WARF Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"SHINE Technologies \/ WARF Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by SHINE Technologies

    Menu

    SHINE Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-ART-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : WARF Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SHINE Partners with UW-Madison, WARF on Kidney and Prostate Cancer Therapies

                            Details : The collaboration aims to create promising new treatments for kidney and prostate cancers. ART-101, a novel prostate cancer treatment developed using SHINE's Ilumira, demonstrates superior efficacy.

                            Brand Name : 177Lu-ART-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 17, 2024

                            Lead Product(s) : 177Lu-ART-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : WARF Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-DOTA-Miltuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Glytherix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GlyTherix Partners with SHINE Technologies For Radiotherapy in Aggressive Cancers

                            Details : Under the terms of agreement, SHINE will supply its n.c.a. Lu-177 chloride, Ilumira, for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers.

                            Brand Name : 177Lu-DOTA-Miltuximab

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : 177Lu-DOTA-Miltuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Glytherix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-rosopatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Telix and SHINE Partner for Lutetium-177 Supply

                            Details : SHINE will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the ...

                            Brand Name : TLX591

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 11, 2022

                            Lead Product(s) : 177Lu-rosopatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            SHINE Technologies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Fidelity Management and Research Company LLC

                            Deal Size : $80.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc

                            Details : Fuding will support SHINE's continued effort to make strong progress in their work to commercialize molybdenum-99, an essential diagnostic isotope, and lutetium-177, a therapeutic isotope that is showing great promise for the treatment of cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 02, 2020

                            Lead Product(s) : Lutetium-177

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Fidelity Management and Research Company LLC

                            Deal Size : $80.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth